AKRO - Akero: Ticking All The Right Boxes In NASH September, 23 2021 08:00 AM Akero Therapeutics Inc. AKRO has continued delivering strong data from its phase 2a trial. Nearest major catalyst is HARMONY trial data in 3Q 2022. The company has a decent amount of cash. For further details see: Akero: Ticking All The Right Boxes In NASH